An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Boston Children's Hospital · Harvard University · +7 more institutions
Abstract
Genome-wide association studies (GWASs) have ascertained numerous trait-associated common genetic variants, frequently localized to regulatory DNA. We found that common genetic variation at BCL11A associated with fetal hemoglobin (HbF) level lies in noncoding sequences decorated by an erythroid enhancer chromatin signature. Fine-mapping uncovers a motif-disrupting common variant associated with reduced transcription factor (TF) binding, modestly diminished BCL11A expression, and elevated HbF. The surrounding sequences function in vivo as a developmental stage-specific, lineage-restricted enhancer. Genome engineering reveals the enhancer is required in erythroid but not B-lymphoid cells for BCL11A expression.…
Citation impact
- FWCI
- 28.58
- Percentile
- 100%
- References
- 54
Authors
18- DEDaniel E. Bauer
Boston Children's Hospital, Harvard University, Dana-Farber Cancer Institute
- SCSophia C. Kamran
Howard Hughes Medical Institute, Harvard University
- SLSamuel Lessard
Montreal Heart Institute
- JXJian Xu
Boston Children's Hospital, Harvard University
- YFYuko Fujiwara
Boston Children's Hospital, Harvard University Press
Topics & keywords
- Enhancer
- Fetal hemoglobin
- Biology
- Genome-wide association study
- Genetics
- Transcription factor
- Chromatin
- Globin